Evidence for Efficacy of Antidepressants for Pain Is Limited
In 11 comparisons, antidepressants were efficacious, but they were inefficacious or evidence was inconclusive for 31 comparisons
Diagnosis & Disease Information
January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
ACP Updates Clinical Guidelines for Major Depressive Disorder Treatment
The updated recommendations include both nonpharmacologic and pharmacologic interventions for adults in the acute phase of MDD.
Antipsychotics Increasingly Being Prescribed to Children
Period prevalence of all antipsychotic prescriptions increased 3.3 percent per year from 2000 to 2019
December 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
Treatment-Resistant Depression Common and Costly
Treatment-resistant depression episodes tied to more psychiatric comorbid conditions, health care utilization, self-harm, and all-cause mortality
Vraylar Approved as Adjunctive Therapy for Major Depressive Disorder
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy.
Intranasal Therapy for Major Depressive Disorder Gets Fast Track Status
The designation is supported by data from 3 clinical studies.
